Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Combinatorial drug screening of mammary cells with induced mesenchymal transformation to identify drug combinations for triple-negative breast cancer.

Colavito SA, Platt JT, Held MA, Liu Z, Sokup R, Stern DF.

Oncotarget. 2019 Aug 6;10(47):4822-4839. doi: 10.18632/oncotarget.27104. eCollection 2019 Aug 6.

2.

Inhibition of isoprenylation synergizes with MAPK blockade to prevent growth in treatment-resistant melanoma, colorectal, and lung cancer.

Theodosakis N, Langdon CG, Micevic G, Krykbaeva I, Means RE, Stern DF, Bosenberg MW.

Pigment Cell Melanoma Res. 2019 Mar;32(2):292-302. doi: 10.1111/pcmr.12742. Epub 2018 Oct 22.

PMID:
30281931
3.

Keeping Tumors Out of the MAPK Fitness Zone.

Stern DF.

Cancer Discov. 2018 Jan;8(1):20-23. doi: 10.1158/2159-8290.CD-17-1243.

4.

GRAPE: a pathway template method to characterize tissue-specific functionality from gene expression profiles.

Klein MI, Stern DF, Zhao H.

BMC Bioinformatics. 2017 Jun 26;18(1):317. doi: 10.1186/s12859-017-1711-z.

5.

p90RSK Blockade Inhibits Dual BRAF and MEK Inhibitor-Resistant Melanoma by Targeting Protein Synthesis.

Theodosakis N, Micevic G, Langdon CG, Ventura A, Means R, Stern DF, Bosenberg MW.

J Invest Dermatol. 2017 Oct;137(10):2187-2196. doi: 10.1016/j.jid.2016.12.033. Epub 2017 Jun 7.

6.

Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.

Langdon CG, Platt JT, Means RE, Iyidogan P, Mamillapalli R, Klein M, Held MA, Lee JW, Koo JS, Hatzis C, Hochster HS, Stern DF.

Mol Cancer Ther. 2017 Jun;16(6):1041-1053. doi: 10.1158/1535-7163.MCT-16-0794. Epub 2017 Mar 14.

7.

A Computational Approach for Identifying Synergistic Drug Combinations.

Gayvert KM, Aly O, Platt J, Bosenberg MW, Stern DF, Elemento O.

PLoS Comput Biol. 2017 Jan 13;13(1):e1005308. doi: 10.1371/journal.pcbi.1005308. eCollection 2017 Jan.

8.

Systematic Drug Screening Identifies Tractable Targeted Combination Therapies in Triple-Negative Breast Cancer.

Wali VB, Langdon CG, Held MA, Platt JT, Patwardhan GA, Safonov A, Aktas B, Pusztai L, Stern DF, Hatzis C.

Cancer Res. 2017 Jan 15;77(2):566-578. doi: 10.1158/0008-5472.CAN-16-1901. Epub 2016 Nov 21.

10.

PMCA2 regulates HER2 protein kinase localization and signaling and promotes HER2-mediated breast cancer.

Jeong J, VanHouten JN, Dann P, Kim W, Sullivan C, Yu H, Liotta L, Espina V, Stern DF, Friedman PA, Wysolmerski JJ.

Proc Natl Acad Sci U S A. 2016 Jan 19;113(3):E282-90. doi: 10.1073/pnas.1516138113. Epub 2016 Jan 4.

11.

Neuregulin-activated ERBB4 induces the SREBP-2 cholesterol biosynthetic pathway and increases low-density lipoprotein uptake.

Haskins JW, Zhang S, Means RE, Kelleher JK, Cline GW, Canfrán-Duque A, Suárez Y, Stern DF.

Sci Signal. 2015 Nov 3;8(401):ra111. doi: 10.1126/scisignal.aac5124.

12.

SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.

Langdon CG, Wiedemann N, Held MA, Mamillapalli R, Iyidogan P, Theodosakis N, Platt JT, Levy F, Vuagniaux G, Wang S, Bosenberg MW, Stern DF.

Oncotarget. 2015 Nov 10;6(35):37410-25. doi: 10.18632/oncotarget.6138.

13.

BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume.

Theodosakis N, Held MA, Marzuka-Alcala A, Meeth KM, Micevic G, Long GV, Scolyer RA, Stern DF, Bosenberg MW.

Mol Cancer Ther. 2015 Jul;14(7):1680-92. doi: 10.1158/1535-7163.MCT-15-0080. Epub 2015 May 6.

14.

The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.

Langdon CG, Held MA, Platt JT, Meeth K, Iyidogan P, Mamillapalli R, Koo AB, Klein M, Liu Z, Bosenberg MW, Stern DF.

Pigment Cell Melanoma Res. 2015 Jul;28(4):417-30. doi: 10.1111/pcmr.12376. Epub 2015 May 6.

15.

PDK1 and SGK3 Contribute to the Growth of BRAF-Mutant Melanomas and Are Potential Therapeutic Targets.

Scortegagna M, Lau E, Zhang T, Feng Y, Sereduk C, Yin H, De SK, Meeth K, Platt JT, Langdon CG, Halaban R, Pellecchia M, Davies MA, Brown K, Stern DF, Bosenberg M, Ronai ZA.

Cancer Res. 2015 Apr 1;75(7):1399-412. doi: 10.1158/0008-5472.CAN-14-2785. Epub 2015 Feb 24.

16.

Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis.

Wali VB, Gilmore-Hebert M, Mamillapalli R, Haskins JW, Kurppa KJ, Elenius K, Booth CJ, Stern DF.

Breast Cancer Res. 2014 Dec 17;16(6):501. doi: 10.1186/s13058-014-0501-z.

17.

Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration.

Haskins JW, Nguyen DX, Stern DF.

Sci Signal. 2014 Dec 9;7(355):ra116. doi: 10.1126/scisignal.2005770.

18.
19.

Enhancing reproducibility in cancer drug screening: how do we move forward?

Hatzis C, Bedard PL, Birkbak NJ, Beck AH, Aerts HJ, Stem DF, Shi L, Clarke R, Quackenbush J, Haibe-Kains B.

Cancer Res. 2014 Aug 1;74(15):4016-23. doi: 10.1158/0008-5472.CAN-14-0725. Epub 2014 Jul 11. Review. Erratum in: Cancer Res. 2014 Sep 15;74(18):5348. Stern, David F [corrected to Stem, David F].

20.

Convergent and divergent cellular responses by ErbB4 isoforms in mammary epithelial cells.

Wali VB, Haskins JW, Gilmore-Hebert M, Platt JT, Liu Z, Stern DF.

Mol Cancer Res. 2014 Aug;12(8):1140-55. doi: 10.1158/1541-7786.MCR-13-0637. Epub 2014 May 14.

21.

Comparison of HER2 and phospho-HER2 expression between biopsy and resected breast cancer specimens using a quantitative assessment method.

Bai Y, Cheng H, Bordeaux J, Neumeister V, Kumar S, Rimm DL, Stern DF.

PLoS One. 2013 Nov 21;8(11):e79901. doi: 10.1371/journal.pone.0079901. eCollection 2013.

22.

EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis.

Breindel JL, Haskins JW, Cowell EP, Zhao M, Nguyen DX, Stern DF.

Cancer Res. 2013 Aug 15;73(16):5053-65. doi: 10.1158/0008-5472.CAN-12-3775. Epub 2013 Jun 21.

23.

MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL.

Tworkoski KA, Platt JT, Bacchiocchi A, Bosenberg M, Boggon TJ, Stern DF.

Pigment Cell Melanoma Res. 2013 Jul;26(4):527-41. doi: 10.1111/pcmr.12110. Epub 2013 May 21.

24.

Genotype-selective combination therapies for melanoma identified by high-throughput drug screening.

Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, Stern DF.

Cancer Discov. 2013 Jan;3(1):52-67. doi: 10.1158/2159-8290.CD-12-0408. Epub 2012 Dec 13.

25.

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.

Krauthammer M, Kong Y, Ha BH, Evans P, Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, Ariyan S, Narayan D, Dutton-Regester K, Capatana A, Holman EC, Bosenberg M, Sznol M, Kluger HM, Brash DE, Stern DF, Materin MA, Lo RS, Mane S, Ma S, Kidd KK, Hayward NK, Lifton RP, Schlessinger J, Boggon TJ, Halaban R.

Nat Genet. 2012 Sep;44(9):1006-14. doi: 10.1038/ng.2359. Epub 2012 Jul 29.

26.

Structural mechanism of the phosphorylation-dependent dimerization of the MDC1 forkhead-associated domain.

Liu J, Luo S, Zhao H, Liao J, Li J, Yang C, Xu B, Stern DF, Xu X, Ye K.

Nucleic Acids Res. 2012 May;40(9):3898-912. doi: 10.1093/nar/gkr1296. Epub 2012 Jan 10.

27.

DNA triplex-mediated inhibition of MET leads to cell death and tumor regression in hepatoma.

Singhal G, Akhter MZ, Stern DF, Gupta SD, Ahuja A, Sharma U, Jagannathan NR, Rajeswari MR.

Cancer Gene Ther. 2011 Jul;18(7):520-30. doi: 10.1038/cgt.2011.21. Epub 2011 Jun 10.

28.

"Competence" progress.

Stern DF.

Mol Cell. 2011 May 20;42(4):411-2. doi: 10.1016/j.molcel.2011.05.001.

29.

NFBD1/MDC1 regulates Cav1 and Cav2 independently of DNA damage and p53.

Wilson KA, Colavito SA, Schulz V, Wakefield PH, Sessa W, Tuck D, Stern DF.

Mol Cancer Res. 2011 Jun;9(6):766-81. doi: 10.1158/1541-7786.MCR-10-0317. Epub 2011 May 6.

30.

Phosphoproteomic screen identifies potential therapeutic targets in melanoma.

Tworkoski K, Singhal G, Szpakowski S, Zito CI, Bacchiocchi A, Muthusamy V, Bosenberg M, Krauthammer M, Halaban R, Stern DF.

Mol Cancer Res. 2011 Jun;9(6):801-12. doi: 10.1158/1541-7786.MCR-10-0512. Epub 2011 Apr 26.

31.

A Variant in a MicroRNA complementary site in the 3' UTR of the KIT oncogene increases risk of acral melanoma.

Godshalk SE, Paranjape T, Nallur S, Speed W, Chan E, Molinaro AM, Bacchiocchi A, Hoyt K, Tworkoski K, Stern DF, Sznol M, Ariyan S, Lazova R, Halaban R, Kidd KK, Weidhaas JB, Slack FJ.

Oncogene. 2011 Mar 31;30(13):1542-50. doi: 10.1038/onc.2010.536. Epub 2010 Nov 29.

32.

EGFs and ERBBs--brief history and prospects.

Stern DF.

Semin Cell Dev Biol. 2010 Dec;21(9):917-21. doi: 10.1016/j.semcdb.2010.10.006. Epub 2010 Oct 21. No abstract available.

33.

Interactions of ErbB4 and Kap1 connect the growth factor and DNA damage response pathways.

Gilmore-Hebert M, Ramabhadran R, Stern DF.

Mol Cancer Res. 2010 Oct;8(10):1388-98. doi: 10.1158/1541-7786.MCR-10-0042. Epub 2010 Sep 21.

34.

Centrosomal Chk2 in DNA damage responses and cell cycle progression.

Golan A, Pick E, Tsvetkov L, Nadler Y, Kluger H, Stern DF.

Cell Cycle. 2010 Jul 1;9(13):2647-56.

35.

Deciphering protein kinase specificity through large-scale analysis of yeast phosphorylation site motifs.

Mok J, Kim PM, Lam HY, Piccirillo S, Zhou X, Jeschke GR, Sheridan DL, Parker SA, Desai V, Jwa M, Cameroni E, Niu H, Good M, Remenyi A, Ma JL, Sheu YJ, Sassi HE, Sopko R, Chan CS, De Virgilio C, Hollingsworth NM, Lim WA, Stern DF, Stillman B, Andrews BJ, Gerstein MB, Snyder M, Turk BE.

Sci Signal. 2010 Feb 16;3(109):ra12. doi: 10.1126/scisignal.2000482.

36.

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells.

Agarwal S, Zerillo C, Kolmakova J, Christensen JG, Harris LN, Rimm DL, Digiovanna MP, Stern DF.

Br J Cancer. 2009 Mar 24;100(6):941-9. doi: 10.1038/sj.bjc.6604937. Epub 2009 Feb 24.

37.

BRCTing up is hard to do.

Stern DF.

Mol Cell. 2009 Jan 30;33(2):137-8. doi: 10.1016/j.molcel.2009.01.005.

38.

ErbB3 is required for ductal morphogenesis in the mouse mammary gland.

Jackson-Fisher AJ, Bellinger G, Breindel JL, Tavassoli FA, Booth CJ, Duong JK, Stern DF.

Breast Cancer Res. 2008;10(6):R96. doi: 10.1186/bcr2198. Epub 2008 Nov 18.

39.

NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathway.

Wilson KA, Stern DF.

Cell Cycle. 2008 Nov 15;7(22):3584-94. Epub 2008 Nov 29.

40.

ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer.

Stern DF.

J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):215-23. doi: 10.1007/s10911-008-9083-7. Epub 2008 May 3. Review.

41.

Production of antibodies that recognize specific tyrosine-phosphorylated peptides.

Digiovanna MP, Stern DF, Roussel RR.

Curr Protoc Immunol. 2002 Nov;Chapter 11:Unit 11.6. doi: 10.1002/0471142735.im0101s50.

PMID:
18432869
42.

Direct resequencing of the complete ERBB2 coding sequence reveals an absence of activating mutations in ERBB2 amplified breast cancer.

Zito CI, Riches D, Kolmakova J, Simons J, Egholm M, Stern DF.

Genes Chromosomes Cancer. 2008 Jul;47(7):633-8. doi: 10.1002/gcc.20566.

43.

Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

DiGiovanna MP, Stern DF, Edgerton S, Broadwater G, Dressler LG, Budman DR, Henderson IC, Norton L, Liu ET, Muss HB, Berry DA, Hayes DF, Thor AD.

J Clin Oncol. 2008 May 10;26(14):2364-72. doi: 10.1200/JCO.2007.13.6580. Epub 2008 Apr 7.

44.

Production of antibodies that recognize specific tyrosine-phosphorylated peptides.

Digiovanna MP, Roussel RR, Stern DF.

Curr Protoc Mol Biol. 2001 May;Chapter 18:Unit 18.6. doi: 10.1002/0471142727.mb1806s50.

PMID:
18265171
45.

Regulation of the Rad53 protein kinase in signal amplification by oligomer assembly and disassembly.

Jia-Lin Ma N, Stern DF.

Cell Cycle. 2008 Mar 15;7(6):808-17. Epub 2008 Jan 8.

PMID:
18239457
46.

Production of antibodies that recognize specific tyrosine-phosphorylated peptides.

DiGiovanna MP, Roussel RR, Stern DF.

Curr Protoc Cell Biol. 2002 Feb;Chapter 16:Unit 16.6. doi: 10.1002/0471143030.cb1606s13. Review.

PMID:
18228399
47.

Stress and compliance with a home exercise program among caregivers of children with disabilities.

Rone-Adams SA, Stern DF, Walker V.

Pediatr Phys Ther. 2004 Fall;16(3):140-8.

PMID:
17057541
48.

Formation of Neu/ErbB2-induced mammary tumors is unaffected by loss of ErbB4.

Jackson-Fisher AJ, Bellinger G, Shum E, Duong JK, Perkins AS, Gassmann M, Muller W, Kent Lloyd KC, Stern DF.

Oncogene. 2006 Sep 14;25(41):5664-72. Epub 2006 May 1.

PMID:
16652155
49.

Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar.

Arbiser JL, Govindarajan B, Battle TE, Lynch R, Frank DA, Ushio-Fukai M, Perry BN, Stern DF, Bowden GT, Liu A, Klein E, Kolodziejski PJ, Eissa NT, Hossain CF, Nagle DG.

J Invest Dermatol. 2006 Jun;126(6):1396-402.

50.

Activation of the checkpoint kinase Rad53 by the phosphatidyl inositol kinase-like kinase Mec1.

Ma JL, Lee SJ, Duong JK, Stern DF.

J Biol Chem. 2006 Feb 17;281(7):3954-63. Epub 2005 Dec 19.

Supplemental Content

Loading ...
Support Center